Ingelheim, Germany

Monika Brink



 

Average Co-Inventor Count = 3.2

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Strasse, DE (1999)
  • Albert-Schweitzer Strasse, DE (2000)
  • Ingelheim, DE (2000 - 2012)
  • Schwabenheim, DE (2014)

Company Filing History:


Years Active: 1999-2014

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Monika Brink: Innovator in Pharmaceutical Chemistry

Introduction

Monika Brink is a distinguished inventor based in Ingelheim, Germany. She has made significant contributions to the field of pharmaceutical chemistry, holding a total of 7 patents. Her work focuses on innovative processes that enhance the synthesis of important pharmaceutical compounds.

Latest Patents

Monika's latest patents include groundbreaking inventions such as the enantioselective synthesis of 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one. This invention relates to a process for the hydrogenation of a ketooxime to selectively form an aminoalcohol stereoisomer. It specifically addresses the hydrogenation of 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7[1H]-trione-6-oxime or a salt thereof to selectively produce a stereoisomer of 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one or a salt thereof. Additionally, her work includes the synthesis of macrolides, particularly a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and its derivatives. This invention also encompasses the development of solvated and non-solvated crystalline forms of the compound, along with their applications in medicaments and treatment methods.

Career Highlights

Throughout her career, Monika has worked with notable companies such as American Cyanamid Company and Intervet International B.V. Her expertise in pharmaceutical chemistry has allowed her to contribute to various innovative projects that have advanced the field.

Collaborations

Monika has collaborated with esteemed colleagues, including Marcus Rainer Knell and Jan Hendrik Wevers. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and innovation.

Conclusion

Monika Brink is a prominent figure in the realm of pharmaceutical inventions, with a strong portfolio of patents that reflect her dedication to advancing medical science. Her innovative approaches continue to

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…